CT/NG Testing Market Size

The market for CT/NG Testing was estimated to be valued at US$ XX Mn in 2021.

The CT/NG Testing Market is estimated to grow at a CAGR of XX% by 2028.

The CT/NG Testing Market is segmented on the basis of Product, Testing Type, Technology, End User, Region.

Based on region, the CT/NG Testing Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the CT/NG Testing Market are CT/NG testing market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of CT/NG infections and the growing investments and funding for R&D in CT/NG diagnosis. , On the other hand, the unfavorable reimbursement scenario and the high cost of instruments and kits may restrain the growth of this market to a certain extent. , CT/NG testing Market Dynamics , DRIVER: Increasing investments and funding to drive market growth , Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the CT/NG testing market. These financial incentives and support systems enable companies to invest in research and development, infrastructure, and the production of advanced diagnostic technologies. By facilitating access to funds, the manufacturers are encouraged to push the boundaries of CT/NG testing, leading to breakthrough innovations in disease detection, monitoring, and personalized medicine. For instance, in April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) stated that it was collaborating with The Body Agency Collective (TBAC) and Visby Medical, Inc., to improve sexually transmitted infection (STI) diagnosis and treatment in observance of National STD Awareness Week. This project will utilize a new PCR diagnostic device which is the Sexual Health Click Test, and it detects three of the most common and curable STIs in women – gonorrhea, chlamydia, and trichomoniasis. , RESTRAINT: High cost of instruments , The entire cost is increased by the variable costs of the required reagents, instruments and those set up by the suppliers. Maintenance and insurance, laboratory supervision, and administrative costs (including rent, office space and administration) are extra costs as well. Only major hospitals and reference laboratories with healthy capital budgets may be able to afford the huge amount of diagnostic equipment. On the other hand, small laboratories, physicians’ offices, and private or individual practitioners encounter capital constraints and therefore, can find it difficult to afford a big or huge instruments and analyzer. Generally, a CT/NG testing kits and instruments can cost between USD 2,000 and USD 80,000. These, costly requirements might hinder the growth of the CT/NG (STI) testing market. , OPPORTUNITY: Growing opportunities in emerging countries , Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the CT/NG testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infections, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries. For example, according to the OECD, the purchasing power of the growing middle-class population is expected to increase to 65% by 2022 from 23% in 2009. This is expected to result in the increasing medical needs of the middle-class population, which will favor market growth. Moreover, as markets in the US and Europe mature, most players will shift their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of CT/NG testing (CT/NG testing). , CHALLENGE: Operational barriers and shortage of skills across major markets , Clinical laboratories are still developing in all; technicians must overcome practical obstacles to ensure efficient sample collection, storage, and transportation. To prevent cross-contamination and maintain efficient time management, laboratory areas must also be redesigned to conduct particular diagnostic procedures used for pathogen detection. This causes maintenance and operation of modern CT/NG devices, particularly those equipped to handle a single sample type, to significantly increase in cost. , Furthermore, clinical laboratories need to embrace cutting-edge technologies capable of quick sample diagnosis due to due to rapid mutation of micro-organisms and the rise in epidemic outbreak. However, the overall adoption of modern molecular diagnostics technologies has hampered, particularly in emerging economies, by the lack of experienced and technically educated laboratory staff. , Assays & kits segment accounted for the largest share of the CT/NG Testing Industry in 2022, by product , Based on product, the CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The high share of this segment is attributed to its in-demand and continuous need for diagnosis and treatment. Due to recurrent purchasing it is a high cost product and thereby adds to the segment growth. , Lab tests segment accounted for the largest share in the CT/NG testing industry in 2022, by testing type , The CT/NG testing market is categorized into lab tests and PoC tests based on test type. In 2022, the lab tests segment held the largest share in the CT/NG testing market, categorized by test type. The growth of this segment can be attributed to factors such as the growing demand for automation in laboratory settings and the increasing incidence of various infectious diseases. , Lab tests are equipped with higher sensitivity and specificity compared to PoC tests. Having a controlled laboratory environment ensures more accurate and sensitive measurements, thereby reducing the chances of false-negative or false-positive results. Another advantage of lab tests is the ability to process a more number of samples simultaneously. Such factors are expected to fuel the growth of this segment. , North America accounted for the largest share of the CT/NG testing industry in 2022 , The CT/NG testing market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the CT/NG testing industry. North America has been at the forefront of technological advancements in the field of diagnostics. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the CT/NG testing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Examples of prominent CT/NG testing companies in North America include Hologic, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US). , Recent Developments in CT/NG Testing Industry , In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases. , In May 2022, Hologic, Inc. (US) acquired Diagenode (US), a developer and manufacturer of molecular diagnostic assays and epigenetics products. This acquisition will further strengthen the company’s molecular diagnostics business by expanding its international capabilities and improving its regional time-to-market. , In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing. , In September 2020, QIAGEN (Netherlands) Acquired NeuMoDx Molecular (US) to expand QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology , KEY MARKET SEGMENTS , By Product , Assays & Kits , Instruments/Analyzers , By Testing Type , Lab Tests , PoC Tests , By Technology , Isothermal Nucleic Acid Amplification Technology , Polymerase Chain Reaction , Immunodiagnostics , Other Technologies , By End User , Diagnostic Laboratories , Hospitals & Clinics , Other End Users , By Region , North America , US , Canada , Europe , Germany , UK , France , Italy , Spain , Rest of Europe , Asia Pacific , China , Japan , India , Rest of Asia Pacific , Latin America , Middle East & Africa , Key Market Players , F. Hoffmann-La Roche Ltd. , Hologic, Inc. , Thermo Fisher Scientific Inc. , Abbott Laboratories , Bio-Rad Laboratories, Inc. , Siemens Healthineers AG Danaher , Becton, Dickinson and Company.